Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.9 USD | -2.04% | -0.08% | +33.89% |
May. 24 | Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing | MT |
May. 21 | Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.89% | 2.83B | |
+17.73% | 124B | |
+16.88% | 111B | |
-9.04% | 23.17B | |
+4.40% | 22.94B | |
-38.15% | 17.42B | |
-7.75% | 17.42B | |
-15.36% | 16.9B | |
+3.42% | 13.71B | |
+29.63% | 11.82B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment